Evelo Biosciences (NASDAQ:EVLO – Get Free Report) is expected to be issuing its resultson Monday, August 31st. Analysts expect Evelo Biosciences to post earnings of ($10.1333) per share for the quarter.
Evelo Biosciences Stock Performance
Evelo Biosciences has a one year low of $0.00 and a one year high of $0.00. The company has a market cap of $2,000.00, a price-to-earnings ratio of -0.00 and a beta of 1.62.
About Evelo Biosciences
Evelo Biosciences is a clinical-stage biotechnology company developing orally delivered immunomodulatory therapies that leverage the gut-body network. The company’s proprietary platform is designed to mimic signals normally generated by gut commensal bacteria to regulate immune function throughout the body. Evelo’s approach focuses on non-live, inactivated microbial derivatives, aiming to offer a new class of biologics that can be administered by mouth and engage mucosal immune pathways to treat a range of diseases.
The company’s pipeline spans inflammatory, autoimmune and oncology indications.
Featured Stories
- Five stocks we like better than Evelo Biosciences
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
